2008
DOI: 10.1016/s1098-3015(10)70498-8
|View full text |Cite
|
Sign up to set email alerts
|

Psy17 the Cost and Cost Effectiveness of Dasatinib (Sprycel) Therapy for the Management of Imatinib Resistant and Intolerant Patients With Chronic Myeloid Leukemia (Cml) in Mexico

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2008
2008
2012
2012

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…However, we identified nine abstracts which met the specified inclusion criteria [209][210][211][212][213][214][215][216][217] and two reports from the SMC. 218,219 Six studies reported on dasatinib [209][210][211][212][213]219 and three reported on nilotinib. 214,215,218 All cost-effectiveness studies considered HDI as the only comparator.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…However, we identified nine abstracts which met the specified inclusion criteria [209][210][211][212][213][214][215][216][217] and two reports from the SMC. 218,219 Six studies reported on dasatinib [209][210][211][212][213]219 and three reported on nilotinib. 214,215,218 All cost-effectiveness studies considered HDI as the only comparator.…”
Section: Resultsmentioning
confidence: 99%
“…Five [209][210][211][212]219 of the six studies of dasatinib concluded that dasatinib dominates (i.e. is more effective and less costly) HDI for people starting in the CP.…”
Section: Summary: Cost-effectiveness Literaturementioning
confidence: 99%